WAT
53
3
IR
83
3
DO
58
6
PRGO
66
9
FSLR
60
5
GOOGL
78
12
GILD
28
2
GME
65
3
HON
53
-4
CPB
42
-3
ETR
58
-2
SEE
46
2
HCA
35
-9
C
46
2
TXT
66
3
HAS
57
-3
LRCX
59
3
SO
59
-3
URBN
70
7
FCX
56
2
WAT
53
3
IR
83
3
DO
58
6
PRGO
66
9
FSLR
60
5
GOOGL
78
12
GILD
28
2
GME
65
3
HON
53
-4
CPB
42
-3
ETR
58
-2
SEE
46
2
HCA
35
-9
C
46
2
TXT
66
3
HAS
57
-3
LRCX
59
3
SO
59
-3
URBN
70
7
FCX
56
2
Financhill
Back

Oncternal Therapeutics Quote, Financials, Valuation and Earnings

Elon's Secret "A.I. 2.0" Project

Click here now to discover how to claim a stake in Elon's "A.I. 2.0" project
Sell
37

ONCT
Oncternal Therapeutics

Last Price:
8.39
Seasonality Move:
0.33%

7 Day Trial

ALL ACCESS PASS

$ 7

This DeFi Coin Could 10x Soon... I Advise You Get In Now!

Discover this DeFi diamond before the next surge

Oncternal Therapeutics Price Quote

$8.39
+0.10 (+-1.81%)
(Updated: April 27, 2024 at 6:15 AM ET)

Oncternal Therapeutics Key Stats

Sell
37
Oncternal Therapeutics (ONCT) is a Sell
Day range:
$8.00 - $8.29
52-week range:
$5.57 - $13.14
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.82%
Volume:
1.4K
Avg. volume:
6.5K
1-year change:
40.08%
Market cap:
$24.5M
Revenue:
$0
EPS:
$-13.43

How Much Does Oncternal Therapeutics Make?

Data Unavailable

Is Oncternal Therapeutics Growing As A Company?

Data Unavailable

Oncternal Therapeutics Stock Price Performance

What Is Oncternal Therapeutics 52-Week High & Low?

Oncternal Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Oncternal Therapeutics?

Is Oncternal Therapeutics Cash Flow Positive?

  • What Is ONCT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$32.2M
  • What Is Oncternal Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1.1M
  • What Is Oncternal Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $651K

Oncternal Therapeutics Return On Invested Capital

Data Unavailable

Oncternal Therapeutics Earnings Date & Stock Price

Oncternal Therapeutics Competitors

Oncternal Therapeutics Dividend Yield

Data Unavailable

Oncternal Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -0.81%
Revenue: 0% 116%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 30.67
Upside from Last Price: 269.92%

Major Shareholders

  • How many ONCT shares are owned by institutional investors?
    8.4M ONCT shares are owned by institutional investors
  • How many ONCT shares are owned by insiders?
    0 ONCT shares are owned by insiders